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OBJECTIVES: Acute bleeds in CHwI patients can be managed with infusions of 
bypassing agents, such as recombinant factor VIIa (rFVIIa). Sequelae of frequent joint 
bleeding include arthropathy, pain and disability. The majority of bleeds are now 
treated at home based on physician recommendations or patient/caregiver experience. 
Consequently, actual treatment patterns and the impact of CHwI on patients and their 
families are not well understood. This study assessed the feasibility of daily collection 
of treatment outcomes as reported by CHwI patients and/or their caregivers. 
METHODS: Frequently-bleeding patients with CHwI (average of ≥4 bleeds over a 
3-month period) prescribed rFVIIa as ﬁrst-line therapy were recruited. Each day, 
patients/caregivers recorded daily activities, QoL (EQ-5D, VAS health/pain), planned 
work or school for the patient/caregiver, family assessment of anxiety/stress and activ-
ity changes via paper diary, and optional electronic interface. When acute bleeds 
occurred, they recorded symptoms, treatment decisions, and absenteeism/lost produc-
tivity. Each medication dose was recorded on an hourly grid including subjective 
status, pain score, and mixing/administration time. Treatments were veriﬁed by com-
parison of product box-tops to diaries. RESULTS: From 52 enrolled patients, 39 
patients (75%) completed diaries for a mean of 105.5 days (median:91; range:66–
180). Patient participation was facilitated by an average of 13 calls/emails per patient 
by a dedicated patient support representative. On average, 13.9% of days were bleed 
days (median:8.2%; range:0–72%). The diary captured 194 bleeding events in 38 
patients; 176 treated hemorrhages (158 rFVIIa-treated). Most bleeds were spontane-
ous (57.4%) and involved joints (69.7%). Thirty-eight patients provided QoL data 
on 3771 of 3777 eligible days. CONCLUSIONS: This study demonstrated the feasibil-
ity of daily diary completion by patients/caregivers with CHwI, providing insights into 
home treatment of CHwI and its impact on patients and their families. High comple-
tion rates were facilitated by dedicated patient support and motivated participants.
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OBJECTIVES: Patients experience acute bleeding episodes that can be managed with 
infusions of BPAs. The study aims to assess impact of hemorrhages on patient/car-
egiver daily activities, absenteeism/productivity, and time spent mixing/administering 
recombinant factor VIIa (rFVIIa) and plasma-derived activated prothrombin complex 
concentrates (pd-aPCC). METHODS: Frequently bleeding CHwI patients (≥4 bleeds 
in 3 months) prescribed rFVIIa as ﬁrst-line treatment, or their caregivers, recorded 
treatments and daily activity changes for 3–6 months including time mixing/adminis-
tering treatments. RESULTS: For 39 diary patients with 188 initial day of bleeds, 
53.7% were reported with activity unchanged, 31.9% slightly changed, 10.6% sig-
niﬁcantly rearranged, and 3.7% majorly changed for patients/caregivers. For bleed 
days 3+, 59.6% reported activity unchanged, 17.0% slightly changed, 7.0% signiﬁ-
cantly changed, and 16.4% majorly changed. On a 10-point scale, median(range) 
interference was: day 1, 2.0(0–10); day 2, 3.0(0–10); and days 3+, 4.0(0–10). Only 
230 of 491 bleeding days were patient work/school days, with 13.5% fully missed, 
3.5% partially missed, and 3.9% unproductive. Only 118 of 229 caregiver bleeding 
days were work/school days, with 9.3% fully missed, 7.6% partially missed, and 
0.8% unproductive. Of 176 BPA-treated bleeding episodes, mixing/administration 
times were reported for 1270 rFVIIa and 80 pd-aPCC injections. Median 
mixing+administration times were 5.0+5.0 min for rFVIIa and 29.0+24.5 min for 
pd-aPCC. Both mixing and administration times were signiﬁcantly shorter for rFVIIa 
(p < 0.0001). The differences were similar for both hemarthroses and muscle bleeds 
and for on-demand only patients (P < 0.0001 for all). CONCLUSIONS: Acute bleed-
ing episodes interfere with patient/caregiver/family activities. However, patients disa-
bled by frequent joint bleeds, and non-working caregivers with multiple children with 
hemophilia may confound simple analysis of work/school interference. An important 
contributor to the impact of CHwI is burden of treatment; results demonstrate a 
signiﬁcant difference per infusion between rFVIIa and pd-aPCC, which parallels the 
package insert recommendations, although limited patient sample size should be 
noted.
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OBJECTIVES: QoL assessments in frequently-bleeding CHwI patients and their fami-
lies are confounded by pre-existing arthropathy and family circumstances. Periodic 
QoL assessments typically made on non-bleed days, may not provide complete reﬂec-
tions of the burden on patients/families. This study evaluates the impact of bleeding 
episodes on patients/caregivers/families and the association between monthly QoL 
scores and patients’ average diary experience. METHODS: Frequently bleeding CHwI 
patients (≥4 bleeds in 3 months) or their caregivers, provided daily assessment of 
EQ-5D (Index, VAS), VAS-pain, and family anxiety/stress/activity change over 3–6 
months. Hierarchical models, stratiﬁcation, and comparison with mean non-bleed 
scores were used to evaluate instrument responsiveness to bleed/non-bleed 
days. RESULTS: QoL data were recorded by 37 of 39 enrolled patients/caregivers 
(3771/3777 eligible diary days, 472 bleed/3299 non-bleed days). Median (range) diary 
duration was 91 (66–180) days, with 8.2% (0–72.2%) bleed days. Median QoL 
parameters were worse (P < 0.0001) on bleed days (Bleed/Non-bleed): EQ-5D index 
(0.75/0.83), VAS (72.5/85.0), VAS-Pain (4.0/1.0), and for all EQ-5D dimensions. 
Trends held at a patient level and within hierarchical models (p < 0.001). Bleed days 
had higher (P < 0.001) proportions of days with abnormalities in family anxiety/stress 
(42% vs. 30%) and family activity changes (34 vs. 21%). Few patients/caregivers 
reported no problems on non-bleed days in EQ-5D Index (13.5%), VAS (2.7%), 
VAS-Pain (27%), family anxiety/stress (37.8%) and family activity changes (43.2%). 
For all patients and bleed types, 70.8% of bleed days had >1 QoL score >1 standard 
deviation (SD) from the patient’s mean non-bleed scores, with 30.9% reporting pain 
scores >1SD from non-bleed baseline. CONCLUSIONS: Assessment of CHwI impact 
on patient/family QoL typically includes periodic (likely non-bleed day) evaluations 
reﬂecting baseline abnormalities. However, daily assessment indicated frequent acute 
bleeds impair QoL beyond patient’s non-bleed day baseline. New approaches are 
required to assess the cumulative impact of acute bleeds during treatment intervals.
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OBJECTIVES: The prevalence of obesity is increasing not only in adults, but in 
children and adolescents. Health and psychosocial issues related to obesity have been 
documented to negatively impact health-related quality of life (HRQoL), which could 
affect children and adolescents differently than adults. This research reviews the litera-
ture on HRQoL instruments utilized in obese children and adolescents. METHODS: 
A systematic search strategy was used to identify published literature between 1997 
and December 2009 via PubMed and Ovid databases. The key terms included obesity, 
quality of life, health-related quality of life, questionnaires, and adolescents. RESULTS: 
A total of 20 studies were retrieved. Fourteen studies were excluded for not including 
an obesity- or weight-speciﬁc questionnaire (n = 12) and assessing the impact of 
another disease or treatment (n = 2). Five obesity- or weight-speciﬁc instruments were 
identiﬁed: Impact of Weight on Quality of Life-Lite (IWQOL-Lite), Impact of Weight 
on Quality of Life-Kids (IWQOL-Kids), Dutch Eating Behavior Questionnaire 
(DEBQ), Sizing Me Up, and Sizing Them Up. All of the instruments were developed 
for children and adolescents, except IWQOL-Lite. Cumulatively, these ﬁve instruments 
measured 17 domains. The most common domains observed in the questionnaires 
were related to Physical Functioning/Comfort, Emotional Functioning, and Social Life. 
Other domains measured were Body Esteem, Family Relations, Mealtime Challenges, 
and School Functioning. The domains that were most impactful in assessing HRQoL 
were Physical Comfort, Body Esteem, and Social Life. The primary outcome of the 
studies demonstrated poor HRQoL in obese children and adolescents. CONCLU-
SIONS: Obesity- and weight-speciﬁc HRQoL instruments are limited, especially for 
children and adolescents. With the increasing prevalence of obesity in this subpopula-
tion, there is a signiﬁcant need for the development of instruments to assess the total 
impact of this disease. The information provided from these instruments can assist 
with future obesity treatment in children and adolescents.
PSY48
THE VALUE TO PATIENTS OF TREATING PLAQUE PSORIASIS
Hauber A1, Gonzalez JM1, Schenkel B2, Loﬂand J3, Martin S3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Johnson & Johnson Pharmaceutical 
Services, LLC, Horsham, PA, USA, 3Centocor Ortho Biotech Services, LLC, Horsham, PA, 
USA
OBJECTIVES: To quantify the value to patients of reducing the severity and size of 
plaque psoriasis (PsO) skin lesions. METHODS: Individuals with a self-reported 
diagnosis of PsO were recruited from a nationally representative household panel. 
Individuals completed a web-based choice-format conjoint analysis survey and were 
